James McCloskey

2.1k total citations · 1 hit paper
65 papers, 805 citations indexed

About

James McCloskey is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, James McCloskey has authored 65 papers receiving a total of 805 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hematology, 25 papers in Genetics and 16 papers in Public Health, Environmental and Occupational Health. Recurrent topics in James McCloskey's work include Acute Myeloid Leukemia Research (30 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Chronic Lymphocytic Leukemia Research (16 papers). James McCloskey is often cited by papers focused on Acute Myeloid Leukemia Research (30 papers), Chronic Myeloid Leukemia Treatments (22 papers) and Chronic Lymphocytic Leukemia Research (16 papers). James McCloskey collaborates with scholars based in United States, Italy and France. James McCloskey's co-authors include Hagop M. Kantarjian, Stefan Faderl, Michael R. Savona, Gary J. Schiller, Mark J. Levis, Terrence Bradley, David P. Steensma, Casey L. O’Connell, Alexander E. Perl and Richard A. Wells and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

James McCloskey

56 papers receiving 794 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

2022 123 citations Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James McCloskey United States	13	500	370	173	166	153	65	805
Georg‐Nikolaus Franke Germany	16	473 0.9×	120 0.3×	118 0.7×	202 1.2×	121 0.8×	69	598
Josefine Palle Sweden	17	659 1.3×	300 0.8×	216 1.2×	84 0.5×	363 2.4×	58	912
Hervé Dombret France	10	640 1.3×	255 0.7×	241 1.4×	142 0.9×	432 2.8×	11	911
Vladan Vučinić Germany	18	518 1.0×	177 0.5×	333 1.9×	153 0.9×	172 1.1×	105	934
R. Schlenk Germany	10	473 0.9×	183 0.5×	96 0.6×	139 0.8×	180 1.2×	20	629
Joe Wiemels United States	8	232 0.5×	351 0.9×	150 0.9×	130 0.8×	361 2.4×	10	871
Man Updesh Singh Sachdeva India	13	245 0.5×	107 0.3×	101 0.6×	185 1.1×	141 0.9×	118	648
M. Schmidt United States	7	1.1k 2.3×	460 1.2×	137 0.8×	548 3.3×	141 0.9×	10	1.3k
H van Kamp Netherlands	15	483 1.0×	266 0.7×	102 0.6×	146 0.9×	110 0.7×	25	883
Marı́a Sara Felice Argentina	15	401 0.8×	140 0.4×	139 0.8×	74 0.4×	497 3.2×	46	736

Countries citing papers authored by James McCloskey

Since Specialization

Citations

This map shows the geographic impact of James McCloskey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James McCloskey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James McCloskey more than expected).

Fields of papers citing papers by James McCloskey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James McCloskey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James McCloskey. The network helps show where James McCloskey may publish in the future.

Co-authorship network of co-authors of James McCloskey

This figure shows the co-authorship network connecting the top 25 collaborators of James McCloskey. A scholar is included among the top collaborators of James McCloskey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James McCloskey. James McCloskey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Narayan, Rupa, Ana Alfonso Piérola, William B. Donnellan, et al.. (2024). First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome. Clinical and Translational Science. 17(3). e13742–e13742. 14 indexed citations

Deininger, Michael W., Jane Apperley, Christopher Arthur, et al.. (2024). Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC.. Journal of Clinical Oncology. 42(16_suppl). 6501–6501.

Naqash, Abdul Rafeh, Reva Schneider, Aditi Shastri, et al.. (2024). Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 42(16_suppl). 3084–3084. 6 indexed citations

Oh, Stephen T., et al.. (2024). MPN-497 Impact of Pacritinib on Symptoms in Thrombocytopenic Myelofibrosis Patients Who Require Red Blood Cell Transfusion. Clinical Lymphoma Myeloma & Leukemia. 24. S436–S436. 1 indexed citations

Garcia‐Manero, Guillermo, Yazan F. Madanat, Mikkael A. Sekeres, et al.. (2024). R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study. Blood. 144(Supplement 1). 4595–4595. 4 indexed citations

Rubin, Joseph, et al.. (2024). Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience. Blood. 144(Supplement 1). 1448–1448.

Sasaki, Koji, Álex Bataller, H. Kantarjian, et al.. (2024). Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials. Blood. 144(Supplement 1). 661–661. 1 indexed citations

Aldoss, Ibrahim, Josep‐María Ribera, Hagop M. Kantarjian, et al.. (2023). Ponatinib Versus Imatinib in Patients with Newly Diagnosed Ph+ ALL: Subgroup Analysis of the Phase 3 Phallcon Study. Blood. 142(Supplement 1). 2871–2871. 2 indexed citations

Vachhani, Pankit, Abdulraheem Yacoub, Elie Traer, et al.. (2023). Platelet Response in Pacritinib-Treated Patients with Cytopenic Myelofibrosis: A Retrospective Analysis of PERSIST-2 and PAC203 Studies. Blood. 142(Supplement 1). 4554–4554. 1 indexed citations

10.

Moslehi, Javid J., Mandar A. Aras, Vivian G. Oehler, et al.. (2023). Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting.. Journal of Clinical Oncology. 41(16_suppl). 7053–7053.

11.

Albitar, Maher, Hong Zhang, Andrew Ip, et al.. (2023). Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors. Heliyon. 9(5). e16261–e16261. 14 indexed citations

12.

Daver, Naval, Alexander E. Perl, Joseph Maly, et al.. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 40(35). 4048–4059. 123 indexed citations breakdown →

13.

Qureshi, Muhammad Asif, Andrew Ip, Wanlong Ma, et al.. (2022). Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence. American Journal Of Pathology. 193(1). 51–59. 12 indexed citations

14.

Ip, Andrew, Wanlong Ma, Andrew L. Pecora, et al.. (2022). Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid Neoplasms. Frontiers in Oncology. 12. 923809–923809. 5 indexed citations

15.

McCloskey, James, et al.. (2021). A Phase 1 Multi-Dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults with Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission with Minimal Residual Disease (MRD) (NCT04310592). Transplantation and Cellular Therapy. 27(3). S161–S162. 1 indexed citations

16.

Altman, Jessica K., James McCloskey, Vamsi Kota, et al.. (2021). Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.. Journal of Clinical Oncology. 39(15_suppl). 7007–7007. 1 indexed citations

17.

Savona, Michael R., Daniel A. Pollyea, Wendy Stock, et al.. (2018). Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. Clinical Cancer Research. 24(10). 2294–2303. 86 indexed citations

18.

McCloskey, James, et al.. (2017). Outcomes with Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired HCVAD-Based Regimen, for Adults Younger Than 50 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood. 130. 5050–5050. 1 indexed citations

19.

Shanmugam, Victoria K., James McCloskey, Beth Elston, Sandra J. Allison, & Jennifer Eng‐Wong. (2011). The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms. Breast Cancer Research and Treatment. 131(2). 699–708. 15 indexed citations

20.

Rettig, Jessica E., et al.. (2005). Seasonal Patterns of Abundance: Do Zooplankton in Small Ponds do the Same Thing Every Spring–Summer?. Hydrobiologia. 556(1). 193–207. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact